%0 Journal Article
%T Prevalence of Precancerous Lesions Based on Digital Cervicography with VIA/VILI among Women Positive for High-Risk Human Papillomavirus Serotypes: A Screening Center-Based Study in Cameroon
%A Jeffrey-Lewis Nzang
%A Cliford Ebontane Ebong
%A Simon Manga
%A Florence Manjuh
%A F&#233
%A lix Essiben
%A Isidore Tompeen
%A Judith Seungue
%A Serge Robert Nyada
%A Jeanne Hortence Fouedjio
%A Ymele Fouelifack
%A Julius Sama Dohbit
%J Open Journal of Obstetrics and Gynecology
%P 967-978
%@ 2160-8806
%D 2024
%I Scientific Research Publishing
%R 10.4236/ojog.2024.146076
%X <b>Background: </b>Since 2021, high-risk Human Papilloma Virus (HR-HPV) testing has been the recommended screening test for cervical cancer for all settings; either used alone in a &#8220;test and treat&#8221; strategy, or with a triage test, with or without biopsy, before treatment. Cameroon has rolled out immunization against HPV 16 and 18, but studies show a higher prevalence of non-16/18 HR-HPV types. <b>Objectives: </b>Determine the prevalence of precancerous lesions, in women with HR-HPV infection and evaluate association of digital cervicography (DC) VIA/VILI positivity with HPV serotype, as a measure of their contribution to precancer and cancer incidence. <b>Methodology: </b>The study was cross-sectional, descriptive, and analytic. It took place at the Etoug-Ebe and Ekoudoum Baptist Hospitals in Yaound&#233;, during the period April-September 2022. We reviewed the records of women screened for cervical cancer between February 2020 and December 2021 and evaluated the prevalence of lesions on digital cervicography (DC) with VIA/VILI for women positive for HR-HPV serotypes. The data were analyzed using SPSS version 20.0 for Windows. P values < 0.05 were considered significant at 95% confidence interval. <b>Results: </b>We identified 315 cases with a positive HR-HPV deoxyribonucleic acid (DNA) test, 224 (71.1%) had a DC VIA/VILI triage test done. Of these, 30 (13.4%) women had a positive DC VIA/VILI, with five women (2.2%) having lesions suggestive of cancer. Out of 11 cases positive for HPV 16 alone, 05 (45.5%) had a positive DC VIA/VILI test. Of the 14 cases positive for HPV 18 alone, 03 (21.4%) had a positive VIA/VILI, meanwhile only 19 (10.7%) of the 177 cases positive for non-16/18 HPV had a positive VIA/VILI test. <b>Conclusion: </b>A high proportion of women (13.4%) with HR HPV had a positive DC VIA/VILI, with a significant proportion (2.2%) having lesions suggestive of invasive cervical cancer HR-HPV serotype was associated with DC VIA/VILI positivity; HPV 16 had the strongest association (45.5%), followed by HPV 18 (21.4%), and non-16/18 HR-HPV (10.7%), suggesting a decreasing order of oncogenicity.
%K High-Risk
%K Human Papillomavirus
%K Precancerous
%K Digital Cervicography
%K VIA/VILI
%K Serotype
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=134068